YAP1 and non-small cell lung carcinoma: Another study showed that the forced overexpression of YAP promotes resistance to EGFR-TKI erlotinib in the NSCLC cell line HCC827 (EGFR exon 19 deletion), and inhibiting YAP enhances the cytotoxicity of erlotinib to the NSCLC cell line H1975 (L858R + T790M mutations) [71].